Developing peptides to target malfunctioning membrane receptors in diseases
Mechanisms of modulation of transmembrane interactions
This study is exploring new ways to create tiny proteins that can help treat cancer and autoimmune diseases by targeting specific receptors in our cells, especially in areas where the environment is more acidic, to either boost or block their activity for better treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Knoxville NIH-funded |
| Lab location | 1 site (Knoxville, United States) |
| Project ID | NIH-11072016 on NIH RePORTER |
What this research studies
This research focuses on creating peptide ligands that can bind to membrane receptors involved in conditions like cancer and autoimmune diseases. The approach involves designing peptides that can either activate or inhibit these receptors by targeting their transmembrane domains, which are crucial for their function. The peptides are engineered to insert into membranes in response to environmental acidity, allowing for precise targeting to affected tissues. Additionally, the research aims to understand the molecular mechanisms behind these interactions and how they can be used to improve therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases or cancers that involve malfunctioning membrane receptors.
Not a fit: Patients with conditions unrelated to membrane receptor dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively modulate receptor activity in various diseases.
How similar studies have performed: Other research has shown promise in using peptide ligands to target membrane receptors, indicating potential for success in this approach.
Where this research is happening
Knoxville, United States
- University of Tennessee Knoxville — Knoxville, United States (Active)
Researchers
- Principal investigator: Barrera, Francisco Nicolas — University of Tennessee Knoxville
- Study coordinator: Barrera, Francisco Nicolas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.